CRISPR/dCas9-based Scn1a gene activation in inhibitory neurons ameliorates epileptic and behavioral phenotypes of Dravet syndrome model mice

Abstract
No abstract available
Funding Information
  • RIKEN Center for Brain Science
  • RIKEN-CBS
  • Takeda Pharmaceutical Company Ltd.
  • AMED (JP18dm0107092)